MCD has an average analyst rating of buy and is -10.43% away from its mean target price of $328.75 per share Its trailing ...

Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease, with its lead program ...

Shivanandan's appointment is expected to bring valuable perspective to Iridium's board, given her early career roots in ...

Megan Graves, who has served as Chief Executive Officer of Hamilton Re since 2020, has decided to retire from the company, ...

D-Wave Quantum Inc. has recently announced a strategic partnership with Yonsei University and Incheon Metropolitan City, ...

Additionally, PureCycle plans to construct a 130-million-pound line in Antwerp, and after integrating the learnings from its ...

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced positive topline results from its phase 2 Explore-CKD trial of ...

These developments mark significant progress for Dyne Therapeutics in its pursuit of accelerated approval for Dyne-101, ...

Based on the unaudited pro forma condensed combined financial information provided in the press release, it is evident that ...

Yum! Brands, Inc. (NYSE: YUM) has announced the appointment of Chris Turner as its new Chief Executive Officer, effective ...

Lucky Strike Entertainment (NYSE: LUCK) has announced that its 2025 summer season pass has experienced significant growth, ...

Novagold Resources Inc. has just released its 2024 Sustainability Report, highlighting the company's environmental, social, ...